Ultime notizie per Nutanix (NASDAQ:NTNX) Azioni

Nutanix

Nutanix Inc is engaged in cloud software, offering organizations a single platform for running applications and managing data, anywhere. Its Nutanix Cloud Platform is designed to enable organizations to build a hybrid multicloud infrastructure, providing a consistent cloud operating model with a single platform for running applications and managing data in core data centers, at the edge, and in public clouds, all while supporting a variety of hypervisors and container platforms. The company is into a single operating and reportable segment that is subscription-based business model. Key revenue is generated from United States.

Nutanix Inc

Oppenheimer analyst Martin Yang maintains Electronic Arts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>) with a Outperform and lowers the price target from $170 to $165.

News

Price Target

Analyst Ratings

Oppenheimer Maintains Outperform on Electronic Arts, Lowers Price Target to $165

On Friday, the U.S. Food and Drug Administration (FDA) approved AstraZeneca Plc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) Datroway&nbsp;(datopotamab deruxtecan or Dato-DXd) for adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy <a target="_blank" href="https://www.benzinga.com//node/43069016" rel="noreferrer noopener">for unresectable or metastatic disease.</a>
The approval was based on results from the&nbsp;TROPION-Breast01&nbsp;Phase 3 trial.
Read Next: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43065029/astrazeneca-aims-to-restore-trust-with-new-leadership-in-china-amid-scandal-and-sales-decline" rel="noreferrer noopener">AstraZeneca Aims to Restore Trust With New Leadership in China Amid Scandal and Sales Decline</a>
In TROPION-Breast01,&nbsp;Datroway&nbsp;significantly reduced the risk of disease progression or death by 37% compared to the investigator&#8217;s choice of chemotherapy as assessed by blinded independent central review (BICR). Median progression-free survival (PFS) was 6.9 months in patients treated with&nbsp;Datroway&nbsp;versus 4.9 months with chemotherapy.
The safety profile of&nbsp;Datroway&nbsp;was consistent with the known profile of this medicine, with no new safety concerns identified.
In the&nbsp;Datroway&nbsp;arm, the interstitial lung disease (ILD) rate was 4.2% and the majority of events were low grade.
Datroway&nbsp;is a specifically engineered TROP2-directed antibody drug conjugate (ADC) discovered by Daiichi Sankyo (OTC:<a class="ticker" href="https://www.benzinga.com/stock/DSNKY#OTC">DSNKY</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/DSKYF#OTC">DSKYF</a>), and being jointly developed and commercialised by AstraZeneca and Daiichi Sankyo.
Recently, the FDA approved&nbsp;AstraZeneca&#8217;s Calquence in combination with bendamustine and rituximab for adult patients with previously untreated mantle cell lymphoma who are ineligible for autologous hematopoietic&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43062308/fda-approves-astrazenecas-calquence-combo-therapy-for-untreated-mantle-cell-lymphoma" rel="noreferrer noopener">stem cell transplantation.</a>
Price Action: AZN stock is up 2.43% at $68.22 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43100176/charles-schwab-delivers-strong-q4-higher-trading-volumes-and-increased-assets-drive-growth" target="_blank" rel="noreferrer noopener">Charles Schwab Delivers Strong Q4: Higher Trading Volumes And New Assets Drive Growth</a></li>
</ul>
Photo via Shutterstock.

Biotech

Equities

Large Cap

Health Care

Movers

Trading Ideas

General

DSKYF

DSNKY

FDA Approves AstraZeneca's Datroway For Pretreated Breast Cancer Patients

Needham analyst Serge Belanger reiterates Evolus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOLS#NASDAQ">EOLS</a>) with a Buy and maintains $22 price target.

Reiteration

EOLS

Needham Reiterates Buy on Evolus, Maintains $22 Price Target

Oppenheimer analyst Martin Yang maintains Take-Two Interactive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTWO#NASDAQ">TTWO</a>) with a Outperform and raises the price target from $190 to $215.

TTWO

Oppenheimer Maintains Outperform on Take-Two Interactive, Raises Price Target to $215

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Politics

Markets

$BTC

$ETH

U.S. SEC Says Acting Chairman Uyeda Announces Formation Of New Crypto Task Force; New Crypto Task Force Will Be Dedicated To Developing A Comprehensive And Clear Regulatory Framework For Crypto Assets; Senior Advisors Gabbert And Asher Will Serve As Task Force's Chief Of Staff And Chief Policy Advisor, Respectively

Traders and investors are watching for Discover Financial Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFS#NYSE">DFS</a>) <a href="https://www.benzinga.com/quote/DFS/earnings">fourth-quarter financial results</a>, confirmed for Wednesday&#8217;s after hours session.
With earnings per share of $3.69 and revenue surpassing expectations at $4.453 billion, Discover in the third quarter benefitted from increased net interest margins and <a href="https://www.benzinga.com/news/earnings/24/10/41369150/discover-reports-better-than-expected-q3-results-higher-delinquency-rates-yoy-details">steady loan growth</a>. 
What To Know From Q3: Credit card loans rose by 3%, and personal loans grew by 9%, contributing to an overall 4% year-over-year loan increase. The company's strategic move to reduce its private student loan portfolio is expected to continue impacting results, but the improved credit profile and net interest income should provide a boost.
While the delinquency rates showed slight increases in both 30+ day and 90+ day categories, Discover&#8217;s risk management initiatives remain a priority. The company&#8217;s Payment Services division, although stable, could see growth from debit transaction volume as PULSE volume increased by 14%. 
As Discover wraps up its student loan portfolio sale, the company could be well-positioned for growth, bolstered by its robust digital banking business and expanding margins.
Read Also: <a href="https://www.benzinga.com/tech/25/01/43092840/tesla-struggles-in-europe-as-new-registrations-fall-13-in-2024-driving-first-global-delivery-decline-in-years">Tesla Struggles in Europe As New Registrations Fall 13% In 2024, Driving First Global Delivery Decline In Years</a>
<h2 class="wp-block-heading">How To Buy DFS Stock</h2>
By now you're likely curious about how to participate in the market for Discover Financial &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so.

If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, DFS has a 52-week high of $189.65 and a 52-week low of $97.70.

What's Going On With Discover Financial Services (DFS) Stock?

Northland Capital Markets analyst Mike Grondahl upgrades LendingTree (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TREE#NASDAQ">TREE</a>) from Market Perform to Outperform and announces $60 price target.

Upgrades

TREE

Northland Capital Markets Upgrades LendingTree to Outperform, Announces $60 Price Target

Intuitive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, announced today it intends to establish a direct presence in Italy, Spain, Portugal, Malta, and San Marino, and associated territories via the acquisition of the da Vinci and Ion distribution businesses in these countries.
Intuitive has entered into this agreement, subject to regulatory approvals, with the current Intuitive technology distributors ab medica, Abex, Excelencia Robotica, and their affiliates to purchase their Intuitive product-related business. The transaction will not close until 2026, after approvals have been received and closing conditions met.

Global

ISRG

Intuitive Announced Acquisition Of Da Vinci And Ion Distribution Businesses In Italy, Spain, Portugal, Malta, And San Marino; Deal Expected To Close By 2026; No Financial Terms Disclosed

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Disc Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRON#NASDAQ">IRON</a>) with a Buy and maintains $118 price target.

IRON

HC Wainwright & Co. Reiterates Buy on Disc Medicine, Maintains $118 Price Target

ScanTech AI Systems, Inc. ("ScanTech" or the "Company") is pleased to announce today the appointment of its new Chief Financial Officer, James White. With more than two decades of experience in private and public company financial reporting, compliance, and operational infrastructure, Mr. White has built a reputation for driving operational excellence and fostering growth.
Mr. White is a seasoned, multi-state Certified Public Accountant (CPA) with a distinguished career spanning over twenty years. As a former Senior Manager in the Assurance Practice at Ernst &amp; Young LLP, he is well-versed in SEC reporting, compliance with the Sarbanes-Oxley Act, PCAOB standards, direct public equity and debt offerings, business combinations and dispositions, as well as internal auditing and corporate governance.

Management

STAI

ScanTech AI Systems Announces The Appointment Of James White As Its New Chief Financial Officer

Contracts

MSFT

ORCL

SFTBY

Softbank CEO Masayoshi Son Is Expected At The White House Tuesday Afternoon, Along With Sam Altman Of OpenAI And Larry Ellison Of Oracle

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Buy and maintains $120 price target.

CYTK

HC Wainwright & Co. Reiterates Buy on Cytokinetics, Maintains $120 Price Target

Keefe, Bruyette &amp; Woods analyst Christopher O'Connell maintains Independent Bank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDB#NASDAQ">INDB</a>) with a Market Perform and lowers the price target from $82 to $80.

INDB

Keefe, Bruyette & Woods Maintains Market Perform on Independent Bank, Lowers Price Target to $80

Revman International, Inc. today announced that it has entered into a license agreement with Tommy&nbsp;Hilfiger a wholly owned subsidiary of PVH Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>), for the development, manufacturing and distribution of new home accessories in the U.S., Canada, and Mexico. The new TOMMY HILFIGER home collection will launch in Spring. The agreement's initial term is through 2029.

Revman Has Entered Into A License Agreement With Tommy Hilfiger, For The Development, Manufacturing And Distribution Of New Home Accessories In The U.S., Canada, And Mexico; The New Tommy Hilfiger Home Collection Will Launch In Spring. The Agreement's Initial Term Is Through 2029.

Whales with a lot of money to spend have taken a noticeably bearish stance on Bank of America.
Looking at options history for Bank of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) we detected 27 trades.
If we consider the specifics of each trade, it is accurate to state that 40% of the investors opened trades with bullish expectations and 55% with bearish.
From the overall spotted trades, 9 are puts, for a total amount of $369,163 and 18, calls, for a total amount of $1,618,410.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $20.0 to $52.5 for Bank of America over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Bank of America's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Bank of America's whale activity within a strike price range from $20.0 to $52.5 in the last 30 days. 
<h3>Bank of America 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737481549_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BAC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$22.55</td>
<td>$22.25</td>
<td>$22.35</td>
<td>$25.00</td>
<td>$447.0K</td>
<td>9.8K</td>
<td align="right">400</td>
</tr>
<tr>
<td>BAC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$9.55</td>
<td>$9.45</td>
<td>$9.45</td>
<td>$40.00</td>
<td>$283.5K</td>
<td>19.4K</td>
<td align="right">812</td>
</tr>
<tr>
<td>BAC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$27.2</td>
<td>$27.1</td>
<td>$27.16</td>
<td>$20.00</td>
<td>$111.3K</td>
<td>33</td>
<td align="right">81</td>
</tr>
<tr>
<td>BAC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$27.2</td>
<td>$27.1</td>
<td>$27.18</td>
<td>$20.00</td>
<td>$95.0K</td>
<td>33</td>
<td align="right">117</td>
</tr>
<tr>
<td>BAC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$9.55</td>
<td>$9.45</td>
<td>$9.45</td>
<td>$40.00</td>
<td>$88.8K</td>
<td>19.4K</td>
<td align="right">317</td>
</tr>
</tbody>
</table>

<h3>About Bank of America</h3>
Bank of America is one of the largest financial institutions in the United States, with more than $3.0 trillion in assets. It is organized into four major segments: consumer banking, global wealth and investment management, global banking, and global markets. Bank of America's consumer-facing lines of business include its network of branches and deposit-gathering operations, retail lending products, credit and debit cards, and small-business services. The company's Merrill Lynch operations provide brokerage and wealth-management services, as does its private bank. Wholesale lines of business include investment banking, corporate and commercial real estate lending, and capital markets operations. Bank of America has operations in several countries but is primarily US-focused.
In light of the recent options history for Bank of America, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Bank of America</h3>
<ul>
<li>With a trading volume of 21,861,047, the price of BAC is up by 0.58%, reaching $46.8.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 84 days from now.</li>
</ul>
<h3>Expert Opinions on Bank of America</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $53.4.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Oppenheimer keeps a Outperform rating on Bank of America with a target price of $54. 
&#x2A; Consistent in their evaluation, an analyst from Truist Securities keeps a Buy rating on Bank of America with a target price of $53. 
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Overweight rating for Bank of America, targeting a price of $58. 
&#x2A; Consistent in their evaluation, an analyst from Piper Sandler keeps a Neutral rating on Bank of America with a target price of $49. 
&#x2A; Showing optimism, an analyst from UBS upgrades its rating to Buy with a revised price target of $53. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Bank of America with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Market Whales and Their Recent Bets on BAC Options

Deep-pocketed investors have adopted a bearish approach towards Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in PFE usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 12 extraordinary options activities for Pfizer. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 33% leaning bullish and 50% bearish. Among these notable options, 5 are puts, totaling $252,236, and 7 are calls, amounting to $697,672.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $20.0 to $35.0 for Pfizer over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Pfizer's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Pfizer's substantial trades, within a strike price spectrum from $20.0 to $35.0 over the preceding 30 days.
<h3>Pfizer Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737481544_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$1.15</td>
<td>$1.12</td>
<td>$1.15</td>
<td>$26.00</td>
<td>$229.8K</td>
<td>16.0K</td>
<td>2.2K</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$0.49</td>
<td>$0.48</td>
<td>$0.48</td>
<td>$27.50</td>
<td>$192.3K</td>
<td>20.5K</td>
<td>4.9K</td>
</tr>
<tr>
<td>PFE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$0.57</td>
<td>$0.55</td>
<td>$0.56</td>
<td>$24.00</td>
<td>$118.9K</td>
<td>6.9K</td>
<td>0</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$1.18</td>
<td>$1.1</td>
<td>$1.1</td>
<td>$35.00</td>
<td>$107.2K</td>
<td>3.3K</td>
<td>1.0K</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$0.54</td>
<td>$0.52</td>
<td>$0.54</td>
<td>$26.50</td>
<td>$56.9K</td>
<td>0</td>
<td>1.2K</td>
</tr>
</tbody>
</table>

<h3>About Pfizer</h3>
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
Following our analysis of the options activities associated with Pfizer, we pivot to a closer look at the company's own performance.
<h3>Current Position of Pfizer</h3>
<ul>
<li>With a trading volume of 13,047,391, the price of PFE is up by 1.08%, reaching $26.59.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 14 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Pfizer</h3>
In the last month, 1 experts released ratings on this stock with an average target price of $29.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from UBS keeps a Neutral rating on Pfizer with a target price of $29. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Pfizer options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Pfizer Unusual Options Activity For January 21

Whales with a lot of money to spend have taken a noticeably bearish stance on Eos Energy Enterprises.
Looking at options history for Eos Energy Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOSE#NASDAQ">EOSE</a>) we detected 12 trades.
If we consider the specifics of each trade, it is accurate to state that 33% of the investors opened trades with bullish expectations and 41% with bearish.
From the overall spotted trades, 2 are puts, for a total amount of $85,230 and 10, calls, for a total amount of $550,497.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $1.0 to $10.0 for Eos Energy Enterprises over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Eos Energy Enterprises's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Eos Energy Enterprises's whale trades within a strike price range from $1.0 to $10.0 in the last 30 days. 
<h3>Eos Energy Enterprises Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737481539_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>EOSE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$1.5</td>
<td>$1.43</td>
<td>$1.5</td>
<td>$5.00</td>
<td>$112.8K</td>
<td>992</td>
<td>248</td>
</tr>
<tr>
<td>EOSE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$1.4</td>
<td>$1.11</td>
<td>$1.11</td>
<td>$10.00</td>
<td>$111.0K</td>
<td>34.5K</td>
<td>1.1K</td>
</tr>
<tr>
<td>EOSE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$1.05</td>
<td>$1.04</td>
<td>$1.04</td>
<td>$5.00</td>
<td>$71.7K</td>
<td>992</td>
<td>2.2K</td>
</tr>
<tr>
<td>EOSE</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$6.05</td>
<td>$5.75</td>
<td>$5.9</td>
<td>$10.00</td>
<td>$57.2K</td>
<td>577</td>
<td>97</td>
</tr>
<tr>
<td>EOSE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$4.3</td>
<td>$4.15</td>
<td>$4.2</td>
<td>$1.00</td>
<td>$56.2K</td>
<td>14.8K</td>
<td>348</td>
</tr>
</tbody>
</table>

<h3>About Eos Energy Enterprises</h3>
Eos Energy Enterprises Inc designs develop, manufactures, and markets zinc-based energy storage solutions for utility-scale, microgrid, and commercial &amp; industrial (C&amp;I) applications. The solutions are used in the utility sector, the renewable energy sector, and the industrial sector. It's flagship product Eos Znyth is a stationary battery energy storage system.
<h3>Current Position of Eos Energy Enterprises</h3>
<ul>
<li>With a volume of 10,282,686, the price of EOSE is down -11.3% at $5.34. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 41 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Eos Energy Enterprises, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

EOSE

Eos Energy Enterprises Options Trading: A Deep Dive into Market Sentiment

<a href="https://www.cbsnews.com/news/trump-announces-private-sector-ai-infrastructure-investment/" title="https://www.cbsnews.com/news/trump-announces-private-sector-ai-infrastructure-investment/">https://www.cbsnews.com/news/trump-announces-private-sector-ai-infrastructure-investment/</a>

'Trump To Announce Private Sector AI Infrastructure Investment; OpenAI, Softbank And Oracle Are Planning A Joint Venture Called Stargate' - CBS News

Roth MKM analyst Sean McGowan initiates coverage on Synergy CHC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNYR#NASDAQ">SNYR</a>) with a Buy rating and announces Price Target of $10.

Initiation

SNYR

Roth MKM Initiates Coverage On Synergy CHC with Buy Rating, Announces Price Target of $10

JetBlue Airways Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBLU#NASDAQ">JBLU</a>) disclosed that it became the first airline to <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b43097149/jetblue-says-just-venmo-us-as-it-becomes-first-airline-to-accept-popular-payment-platform-for-onli" rel="noreferrer noopener">accept Venmo for online flight bookings</a>.
The company stated that U.S. travelers can use their Venmo balance or linked payment methods to purchase flights, which is now available on the company website and coming soon to the mobile app.
John Anderson, senior vice president and general manager of consumer, PayPal stated, &#8220;The added ability to pay with Venmo for flights on JetBlue and manage travel costs during the trip through&nbsp;Groups&nbsp;helps solve the pain points of shared expenses from the time of booking to returning home.&#8221;
JetBlue's partnership with Venmo is part of its ongoing effort to enhance the digital travel experience.
Notably, in September 2024, the airline added features to its mobile app, including a boarding countdown on lock screens and improved access to gate information.
Last week, JetBlue&nbsp;added new cities and new routes to its network to offer customers more options for summer travels, which includes first-ever flights to Halifax, Nova Scotia, Canada <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b43002617/jetblue-enhances-summer-travel-with-new-routes-and-destinations-strengthening-its-east-coast-netwo" rel="noreferrer noopener">and San Pedro Sula, Honduras</a>.
The company plans to release fourth-quarter earnings <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">results on January 28, 2025</a>.
Investors can gain exposure to the stock via&nbsp;Themes Airlines ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRL#NASDAQ">AIRL</a>) and U.S. Global Jets ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JETS#NYSE">JETS</a>).
Price Action: JBLU shares are up 6.02% at $8.10 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/travel/25/01/43062173/bank-of-america-delta-united-to-lead-airline-industry-in-2025" target="_blank" rel="noreferrer noopener">Bank Of America: Delta, United To Lead Airline Industry In 2025</a></li>
</ul>
Photo via Shutterstock.

Travel

AIRL

JBLU

JETS

JetBlue To Bring Venmo Onboard For Online Bookings: Details

Cloudflare, Nutanix, Twilio among top automation software stocks for 2025: Piper Sandler

High quality cyclical stocks according to Morgan Stanley

Barclays lays out 2025 thoughts on Apple, networking and other areas of tech

Selecting the best stocks is akin to visiting an apple orchard in the fall. Arrive at the right time, and you'll find the finest fruit still hangin...

TipRanks' 'Perfect 10' List: Unveiling 2 High-Scoring Stocks for 2025

Cloud stocks are a strong investment this year due to increasing demand, emerging technologies, accelerated adoption, and market growth, which makes under-the-radar companies like Nutanix (NTNX), Smartsheet (SMAR), and Sprinklr (CXM) appealing to investors seeking robust growth opportunities. Read on... The COVID-19 pandemic accelerated the adoption of cloud services as remote work became a necessity, fueling demand for scalable and accessible solutions. Multi-cloud strategies now enable organizations to optimize operations, enhance data resilience, and reduce risks, making the cloud sector a compelling investment opportunity.
In this context, under-the-radar cloud stocks like Nutanix, Inc. (<a href="https://stocknews.com/stock/NTNX/">NTNX</a>), Smartsheet Inc. (<a href="https://stocknews.com/stock/SMAR/">SMAR</a>), and Sprinklr, Inc. (<a href="https://stocknews.com/stock/CXM/">CXM</a>) stand poised for growth.
In today's tech-driven market, cloud computing replaces physical storage with accessible, cost-effective solutions for seamless data management. The public cloud services market is projected to grow by 21.5% in 2025. Gartner forecasts that by 2027, <a href="https://www.gartner.com/en/newsroom/press-releases/2024-11-19-gartner-forecasts-worldwide-public-cloud-end-user-spending-to-total-723-billion-dollars-in-2025#:~:text=All%20Cloud%20Segments%20to%20Record%20Double%2DDigit%20Growth%20in%202025&amp;text=%E2%80%9CCloud%20use%20cases%20continue%20to,21.5%25%20growth%20in%202025.%E2%80%9D">90% of organizations</a> will adopt hybrid cloud approaches, with data synchronization across hybrid environments emerging as a critical GenAI challenge to address.
Notably, the cloud enables businesses to adopt innovative models such as Blockchain-as-a-Service (BaaS) and supports flexible, secure, and scalable operations. Meanwhile, cloud-based applications and software services remain among the largest spending segments currently. Spending on SaaS applications is expected to reach <a href="https://finance.yahoo.com/news/cloud-spending-reach-staggering-723bn-110300560.html">$299.10 billion this year</a>, up from just over $250.80 billion in 2024.
Furthermore, emerging technologies such as quantum computing and confidential computing offer scalability, resilience, and advanced security features, fostering confidence in cloud adoption and investment. Considering these favorable trends, let's assess the fundamentals of the aforementioned cloud stocks.
Nutanix, Inc. (<a href="https://stocknews.com/stock/NTNX/">NTNX</a>) 
NTNX provides an enterprise cloud platform internationally. The company offers a hyper-converged infrastructure software stack, including Acropolis Hypervisor, flow virtual networking and security, Nutanix Kubernetes Engine, and Nutanix Cloud Clusters.
On November 12, 2024, NTNX announced Nutanix Enterprise AI, a unified generative AI platform deployable across on-premises, edge, and public clouds. It enables secure, efficient AI application deployment with optimized performance and a consistent multicloud operating model.
On November 7, 2024, NTNX announced an expanded strategic collaboration with AWS to simplify cloud migration and enable on-premises customers to leverage AWS services through Nutanix Cloud Clusters (NC2) on AWS. This partnership aims to accelerate digital transformation with enhanced scalability, security, and hybrid cloud capabilities.
In terms of the trailing-12-month gross profit margin, NTNX's 85.44% is 69.6% higher than the 50.38% industry average. Its 15.07% trailing-12-month <a href="https://www.investopedia.com/terms/l/levered-free-cash-flow.asp">levered FCF</a> margin is 32.5% higher than the 11.38% industry average. Additionally, its 10.07% trailing-12-month Return on Total Capital is 230.2% higher than the industry average of 3.05%.
NTNX's revenue grew at a CAGR of 15.1% over the past three years. Similarly, its levered FCF grew at a CAGR of 21.8% during the same period.
NTNX's total revenue for the first quarter, which ended on October 31, 2024, was $590.96 million, up 15.6% year-over-year. The company's gross profit rose 18.5% from the year-ago value to $508.29 million for the same period. Additionally, its non-GAAP net income came in at $121.77 million, or $0.42 per share, up 43.2% and 44.8%, respectively, compared to the prior-year quarter.
For the quarter ending January 31, 2025, NTNX's revenue is expected to increase 13.6% year-over-year to $642.08 million. Its EPS for the same quarter is expected to increase 2.4% year-over-year to $0.47. It surpassed the Street EPS estimates in each of the trailing four quarters. Over the past year, the stock has gained 24.5% to close the last trading session at $62.61.
NTNX's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect a favorable outlook. It has an overall rating of A, translating to a Strong Buy in our proprietary rating system. The POWR Ratings assess stocks by 118 different factors, each with its own weighting.
NTNX has an A grade for Growth and Quality and a B for Momentum. It is ranked #15 out of 125 stocks in the B-rated <a href="https://stocknews.com/category/software-application/">Software – Application</a> industry. To access additional grades for NTNX's Value, Stability, and Sentiment, <a href="https://stocknews.com/stock/NTNX/">click here</a>.
Smartsheet Inc. (<a href="https://stocknews.com/stock/SMAR/">SMAR</a>) 
SMAR provides an enterprise platform to plan, capture, manage, automate, and report on work for teams and organizations.
SMAR's levered FCF grew at a CAGR of 38.6% over the past three years. Similarly, its revenue grew at a CAGR of 29.1% during the same period.
In terms of the trailing-12-month levered FCF margin, SMAR's 27.21% is 139.1% higher than the 11.38% industry average. Likewise, its 81.68% trailing-12-month gross profit margin is 62.1% higher than the 50.38% industry average. Additionally, its 0.82x trailing-12-month asset turnover ratio is 34.35% higher than the industry average of 0.61x.
In the fiscal third quarter that ended October 31, 2024, SMAR's revenue stood at $286.87 million, up 16.7% year-over-year, and non-GAAP operating income rose 191.2% year-over-year to $56.36 million. In addition, the company's non-GAAP net income amounted to $61.04 million and $0.44 per share, reflecting increases of 170.3% and 158.8% year-over-year, respectively.
Analysts expect SMAR's EPS and revenue for the quarter ending January 31, 2024, to increase 0.8% and 14.9% year-over-year to $0.34 and $295.29 million, respectively. It surpassed the Street EPS and revenue estimates in each of the trailing four quarters. SMAR's stock has gained 49.5% over the past nine months to close the last trading session at $56.33.
SMAR's positive prospects are reflected in its POWR Ratings. It has an overall rating of B, equating to a Buy in our proprietary rating system.
It is ranked #6 out of 18 stocks in the A-rated <a href="https://stocknews.com/category/software-saas/">Software – SAAS</a> industry. It has an A grade for Growth and a B for Sentiment and Quality. To see SMAR's Value, Momentum, and Stability ratings, <a href="https://stocknews.com/stock/SMAR/">click here</a>.
Sprinklr, Inc. (<a href="https://stocknews.com/stock/CXM/">CXM</a>)
CXM provides enterprise cloud software products worldwide. The company operates Unified Customer Experience Management platform, a software that enables customer-facing teams to collaborate across internal silos, communicate across digital channels, and leverage a complete suite of capabilities to deliver customer experiences.
CXM's total assets grew at a CAGR of 4.7% over the past three years. Also, its revenue grew at a CAGR of 19.6% over the past three years.
In terms of the trailing-12-month Return on Total Capital, CXM's 3.09% is 1.3% higher than the 3.05% industry average. Similarly, its 4.54% trailing-12-month Return on Total Assets is 123.4% higher than the industry average of 2.03%. Its 5.59% trailing-12-month net income margin is 45.9% higher than the industry average of 3.83%.
For the fiscal third quarter of 2025, which ended on October 31, 2024, CXM's total revenue increased by 7.7% year-over-year to $200.69 million. Its non-GAAP gross profit rose by 2.2% from the prior year to $143.61 million. Additionally, the company's non-GAAP net income and non-GAAP net income per share were $25.85 million and $0.10, respectively.
Street expects CXM's revenue for the quarter ending January 31, 2025, to increase 3.3% year-over-year to $200.56 million. Its EPS for the quarter ending July 31, 2025, is expected to rise 47.2% year-over-year to $0.09. It surpassed the consensus EPS estimates in three of the trailing four quarters. Over the past three months, the stock has gained 14.3% to close the last trading session at $8.26.
CXM's POWR Ratings reflect its robust fundamentals. It has an overall rating of B, which translates to a Strong Buy in our proprietary rating system.
It is ranked #43 in the Software - Application industry. It has a B grade for Value and Momentum. <a href="https://stocknews.com/stock/CXM/">Click here</a> to see CXM's Growth, Stability, Sentiment, and Quality ratings.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
NTNX shares were trading at $62.83 per share on Tuesday afternoon, up $0.22 (+0.35%). Year-to-date, NTNX has gained 2.70%, versus a -0.90% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Abhishek Bhuyan</h2> <img src='https:/wp-content/uploads/2023/07/ABhuyan.jpg' style="float:left; padding:5px;width:125px;">Abhishek embarked on his professional journey as a financial journalist due to his keen interest in discerning the fundamental factors that influence the future performance of financial instruments.<a href="https://stocknews.com/authors/?author=abhishek-bhuyan">More...</a>The post <a href=https://stocknews.com/news/ntnx-smar-cxm-3-under-the-radar-cloud-stocks-poised-for-growth/>3 Under-the-Radar Cloud Stocks Poised for Growth</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Under-the-Radar Cloud Stocks Poised for Growth

Raymond James lowered the firm's price target on Nutanix (NTNX) to $76 from $83 and keeps an Outperform rating on the shares. The firm's fundamenta...

Nutanix price target lowered to $76 from $83 at Raymond James

Raymond James analyst Simon Leopold maintained a Buy rating on Nutanix (NTNX – Research Report) today and set a price target of $76.00. The company...

Raymond James Reaffirms Their Buy Rating on Nutanix (NTNX)

AAPL

ALLY

ANET

AVGO

AVTR

AXON

CIEN

CSCO

CVLT

DASH

DELL

DGII

EWBC

FFIV

FLEX

FTNT

GOOGL

HBAN

HLIT

HOOD

HUBS

IDXX

JNPR

KEYS

NFLX

NTAP

NTNX

NVDA

PODD

PSTG

RBRK

SMAR

SPOT

SPSC

TEAM

TRGP

TWLO

UMBF

ZBRA

Press Releases

DevRev Designs SaaS 2.0 With a Conversational Interface on Its AI-Native Platform

Nutanix is Positioned Furthest in Vision Among All Vendors in 2024 Gartner® Magic Quadrant™ for File and Object Storage Platforms

Nutanix Expands Partnership with AWS

Nutanix Announces Date and Conference Call Information for First Quarter Fiscal Year 2025 Financial Results

Nutanix Extends AI Platform to Public Cloud

Earnings

Nutanix Reports First Quarter Fiscal 2025 Financial Results

Nutanix to Present at Upcoming Investor Conference

Nutanix Announces Proposed $750 Million Convertible Senior Notes Offering

Nutanix Announces Pricing of $750 Million 0.50% Convertible Senior Notes

ADBE

Adobe

Autodesk

Ansys

Applovin Corporation - Class A Common Stock

AppLovin

Aspen Technology

Cadence Design Systems, Inc. - Common Stock

Cadence Design Sys

Salesforce

Datadog

DocuSign

Dynatrace

Fair Isaac

HubSpot

Intuit

Samsara

Manhattan Associates, Inc. - Common Stock

Manhattan Associates

MicroStrategy Incorporated - Class A Common Stock

MicroStrategy

Palantir Technologies Inc. - Class A Common Stock

Palantir Technologies

Roper Techs

Synopsys

Atlassian Corporation - Class A Common Stock

Atlassian

Tyler Technologies

Workday

Zoom Communications, Inc. - Class A Common Stock

Zoom Communications

Raymond James

Morgan Stanley

Wells Fargo

Piper Sandler

Comments

Nutanix

Notizie

Ultime notizie per Nutanix (NASDAQ:NTNX) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO